NDA 218550 · Genentech INC
Rozlytrek
Entrectinib · Oral
Accelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 20, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
38
6 Phase 3, 12 recruiting
FAERS reports
1,691
1,103 serious, 275 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1.1 ) Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) 1.1 ROS1 -Positive Non-Small Cell Lung Cancer ROZLYTREK is indicated for the treatment of adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. 1.2 NTRK Gene Fusion-Positive Solid Tumors ROZLYTREK is indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the...
Mechanism: Entrectinib is an inhibitor of the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC (encoded by the neurotrophic tyrosine receptor kinase [ NTRK ] genes NTRK1, NTRK2, and NTRK3 , respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK) with IC 50 values of 0.1 to 2 nM. Entrectinib also inhibits JAK2 and TNK2 with IC 50 values > 5 nM. The major active metabolite of entrectinib, M5, showed similar in vitro activity against TRK, ROS1, and ALK. Fusion proteins that include TRK, ROS1, or ALK kinase domains can drive tumorigenic...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2023 Original approval · Type 3 - New Dosage Form · priority review Accelerated approvalOrphanLetterReview
1 products under this application
- ROZLYTREK · ENTRECTINIB 50MG/PACKET · PELLETS, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Entrectinib" as an intervention, any sponsor and status, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03178552 · 1,000 participants (planned) · Start Sep 22, 2017 · Primary completion Jun 30, 2027
Drug: Alectinib; Atezolizumab and 10 more · For: Non-Small Cell Lung Cancer
Sites: Sacramento, California; Denver, Colorado; Fort Myers, Florida · 161 sites in all
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04589845 · 920 participants (planned) · Start Jan 18, 2021 · Primary completion Sep 25, 2032
Drug: Entrectinib; Entrectinib and 9 more · For: Solid Tumors
Sites: Goodyear, Arizona; Los Angeles, California; Newport Beach, California · 112 sites in all
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolPivotal-lookingRecruiting
Cancer Research UKAcademic, hospital or other
NCT05722886 · 825 participants (planned) · Start Mar 1, 2023 · Primary completion Oct 2029
Drug: Alectinib; Atezolizumab and 5 more · For: Haematological Malignancy; Solid Tumour
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Bristol, United Kingdom · 27 sites in all
Fudan UniversityAcademic, hospital or other
NCT06195228 · 800 participants (planned) · Start Jan 1, 2020 · Primary completion Dec 31, 2026
Drug: dabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy and 4 more · For: Advanced Thyroid Cancer Patients Who Received Target Therapy
Sites: Fuzhou, China; Zhengzhou, China; Wuhan, China · 8 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02568267 · 534 participants · Start Nov 19, 2015 · Primary completion Oct 29, 2026
Drug: Entrectinib · For: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer and 13 more
Sites: Phoenix, Arizona; Duarte, California; La Jolla, California · 115 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use173
- dizziness157
- death135
- disease progression119
- taste disorder74
- no adverse event72
- drug ineffective69
- constipation68
- blood creatinine increased66
- fatigue64
- diarrhoea63
- renal impairment62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 32 |
| 2020 | 125 |
| 2021 | 233 |
| 2022 | 288 |
| 2023 | 263 |
| 2024 | 467 |
| 2025 | 172 |
| 2026 | 109 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rozlytrek (Entrectinib)
2024 spending
$19.1M
Beneficiaries
239
1,135 claims
Per beneficiary
$79,818
$219.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,000,980 |
| 2021 | $9,829,447 |
| 2022 | $12,257,995 |
| 2023 | $15,596,859 |
| 2024 | $19,076,487 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.
Ahn BC, Kim YJ, Lee Y, et al. · JAMA Oncol 2026 · Multicenter Study, Clinical Trial, Phase II
- Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S, Gadgeel SM, Mok T, et al. · Nat Med 2024 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, et al. · Cancer Discov 2017 · Clinical Trial, Phase II
- Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Chu P, Antoniou M, Bhutani MK, et al. · J Comp Eff Res 2020 · Comparative Study, Research Support, Non-U.S. Gov't
- Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Desai AV, Robinson GW, Gauvain K, et al. · Neuro Oncol 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
González-Sales M, Djebli N, Meneses-Lorente G, et al. · Cancer Chemother Pharmacol 2021 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.